The central role of TFEB in the regulation of ALP activity made the transcription factor an attractive tool to treat lysosomal storage diseases, such as Alzheimer’s disease, amyotrophic lateral sclerosis, Gaucher disease, and Pompe’s disease [22,24,25,46,47,48]. Here, TFEB is linked to early-onset autosomal dominant Alzheimer disease.